GM-CSF Gene-Edited CAR-T Data to be Presented at International Society for Cell & Gene Therapy Annual Meeting 2021
May 26 2021 - 8:30AM
Business Wire
Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage
biopharmaceutical company focused on preventing and treating an
immune hyper-response called ‘cytokine storm’ with its lead drug
candidate, lenzilumab™, today announced that granulocyte
macrophage-colony stimulating factor (GM-CSF) gene-edited CAR-T
data will be presented at the International Society for Cell &
Gene Therapy (ISCT) 2021 Annual Meeting which will be held in New
Orleans from May 26- 28, 2021.
Researchers at the Mayo Clinic, Rochester, MN have demonstrated
that CRISPR/Cas9 GM-CSF knock-out in CAR-T cells (GM-CSFKO CAR-T)
dampens CAR-T cell early activation and reduces activation-induced
cell death (AICD), resulting in enhanced antigen-specific T-cell
expansion in vivo. The modulation of intrinsic pathways is not due
to an off-target effect and provides additional mechanistic
rationale for the improved anti-tumor activity observed with
GM-CSFKO CAR-T.
“These findings highlight the intrinsic value of GM-CSFKO CAR-T
as a novel, potentially more effective and less toxic platform to
enhance current CAR-T cell therapies,” said Cameron Durrant, MD,
MBA, chief executive officer of Humanigen.
Mayo Clinic researchers will present their research entitled,
“GM-CSF disruption in CAR-T cells ameliorates CAR-T cell activation
and reduces activation-induced cell death,” on May 28, 2021 from
11:30 AM to 1:00 PM ET as part of the session titled “Novel
Allo-Engineering Approaches and Progress in Off-the-Shelf
Products.”
“Mayo Clinic is enthusiastic about these findings, and they
provide us with valuable information to enhance our current CAR-T
cell therapies,” said Saad S. Kenderian, MD, Division of
Hematology, Mayo Clinic.
Details for the upcoming event are below:
ISCT 2021 New Orleans VIRTUAL Meeting
Novel Allo-Engineering Approaches and
Progress in Off-the-Shelf Products Session Date: Friday, May 28,
2021 Time: 11:30 AM ET
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and
pre-clinical therapies for the treatment of cancers and infectious
diseases via its novel, cutting-edge GM-CSF neutralization and
gene-knockout platforms. Humanigen’s immediate focus is on the
development of lenzilumab as a therapy for hospitalized, hypoxic
COVID-19 patients. Humanigen recently announced plans to initiate a
randomized, multicenter, potentially registrational, Phase 2 study
to evaluate the efficacy and safety of lenzilumab combined with all
commercially available CD19 CAR-T therapies in diffuse large B-cell
lymphoma.
Humanigen is also focused on creating next-generation
combinatory gene-edited CAR-T therapies using strategies to improve
efficacy while employing GM-CSF gene knockout technologies to
control toxicity. In addition, Humanigen is developing its own
portfolio of proprietary first-in-class EphA3-CAR-T for various
solid cancers and EMR1-CAR-T for various eosinophilic disorders.
Humanigen is also exploring the effectiveness of its GM-CSF
neutralization technologies (either through the use of lenzilumab
as a neutralizing antibody or through GM-CSF gene knockout) in
combination with other CAR-T, bispecific or natural killer (NK) T
cell engaging immunotherapy treatments to break the
efficacy/toxicity linkage, including to prevent and/or treat
graft-versus-host disease (GvHD) in patients undergoing allogeneic
hematopoietic stem cell transplantation (HSCT). For more
information, visit www.humanigen.com and follow Humanigen on
LinkedIn, Twitter and Facebook.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment, and expectations regarding future
performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct, and
you should be aware that actual events or results may differ
materially from those contained in the forward-looking statements.
Words such as "will," "expect," "intend," "plan," "potential,"
"possible," "goals," "accelerate," "continue," and similar
expressions identify forward-looking statements, including, without
limitation, statements regarding the timing for submission of
applications for EUA and BLA, and for conditional marketing
authorization in the UK and EU, as well as statements regarding
Humanigen’s beliefs relating to the technologies in Humanigen’s
current pipeline.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to, the risks inherent in
the company’s lack of profitability and potential need for
additional capital to grow its business; its dependence on partners
to further the development of its product candidates; the
uncertainties inherent in the development, attainment of the
requisite regulatory authorizations and approvals and launch of any
new pharmaceutical product; the outcome of pending or future
litigation; and the various risks and uncertainties described in
the "Risk Factors" sections and elsewhere in Humanigen's periodic
and other filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not rely upon any
forward-looking statements as predictions of future events. The
company undertakes no obligation to revise or update any
forward-looking statements made in this presentation to reflect
events or circumstances after the date hereof, to reflect new
information or the occurrence of unanticipated events, to update
the reasons why actual results could differ materially from those
anticipated in the forward-looking statements, in each case, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210526005328/en/
Humanigen Media Grace Catlett RXMD Gcatlett@rxmedyn.com
516-318-8563
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024